Pulmonary Arterial Hypertension Market 2017 Competitor Information, Analysis, and Insights to Improve R&D Strategies 2026

Pune, India, 29th November 2017: WiseGuyReports announced addition of new report, titled “EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2026”.

Summary
Pulmonary Arterial Hypertension (PAH) is a rare and severe condition characterized by vascular proliferation and remodeling of the small pulmonary arteries. This results in progressively increasing pulmonary vascular resistance, leading to an increase in pulmonary arterial pressure. The disease typically results in right-sided heart failure and premature death

To forecast the diagnosed incident and diagnosed prevalent cases of PAH in the 7MM, epidemiologists selected nationally representative, registry-based studies and Ministry of Health statistics studies that provided the diagnosed incidence and/or diagnosed prevalence of PAH in the 7MM. For the US and 5EU (France, Germany, Italy, Spain, and UK), epidemiologists provide two different forecasts for the diagnosed incident and diagnosed prevalent cases of PAH-a forecast based on registry data and a forecast adjusted for the underestimation of registry-based data.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2536122-epicast-report-pulmonary-arterial-hypertension-epidemiology-forecast-to-2026

Epidemiologists forecast an increase in the adjusted diagnosed incident cases of PAH in the 7MM, from 11,271 adjusted diagnosed incident cases in 2016 to 11,659 adjusted diagnosed incident cases in 2026, at an annual growth rate (AGR) of 0.34% during the forecast period.

Scope
- The Pulmonary arterial hypertension (PAH) EpiCast Report provides an overview of the risk factors and global trends of PAH in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- It includes a 10-year epidemiological forecast for the diagnosed incident cases of PAH and diagnosed prevalent cases of PAH, segmented by age (at 10-year intervals, for all ages) and sex. The diagnosed prevalent cases are further segmented according to the New York Heart Association (NYHA) functional classes I-IV, and comorbidities (connective tissue disease, systemic sclerosis, diabetes, chronic obstructive pulmonary disease, portal hypertension, and congenital heart disease).
- The PAH epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The PAH EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global PAH market.
- Quantify patient populations in the global PAH market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PAH therapeutics in each of the markets covered.
- Understand magnitude of PAH population by disease comorbidity.

Table of Content: Key Points
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Pulmonary Arterial Hypertension: Executive Summary 5
2.1 Related Reports 7
2.2 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 11
3.3 Global and Historical Trends 11
3.4 Forecast Methodology 13
3.4.1 Sources 13
3.4.2 Forecast Assumptions and Methods 21
3.4.3 Diagnosed Incident Cases and Diagnosed Prevalent Cases of PAH (Forecast Based on Registry Data) 22
3.4.4 Diagnosed Prevalent Cases of PAH by NYHA Functional Class I-IV, 7MM (Forecast Based on Registry Data) 26
3.4.5 Diagnosed Prevalent Cases with Comorbidities (Forecast Based on Registry Data) 28
3.4.6 Diagnosed Incident Cases and Diagnosed Prevalent Cases - US, France, Germany, Italy, Spain, and UK (Forecast Adjusted for Underestimation of Registry Data) 30
3.4.7 Diagnosed Prevalent Cases by NYHA Functional Class I-IV, US, France, Germany, Italy, Spain, and UK (Forecast Adjusted for Underestimation of Registry Data) 31
3.4.8 Diagnosed Prevalent Cases by Comorbidities (Adjusted for Underestimation) 31
3.5 Epidemiological Forecast for PAH (2016-2026) - Based on Registry Data 31
3.5.1 Diagnosed Incident Cases of PAH (Forecast Based on Registry Data) 31
3.5.2 Diagnosed Prevalent Cases of PAH (Forecast Based on Registry Data) 32
3.5.3 Diagnosed Prevalent Cases of PAH by NYHA Functional Classes (Forecast Based on Registry Data) 33
3.5.4 Comorbidities Among the Diagnosed Prevalent Cases of PAH (Forecast Based on Registry Data) 34
3.6 Epidemiological Forecast for PAH (2016-2026) - Adjusted for Underestimation of Registry Data 34
3.6.1 Diagnosed Incident Cases of PAH (Forecast Adjusted for Underestimation of Registry Data) 34
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2536122-epicast-report-pulmonary-arterial-hypertension-epidemiology-forecast-to-2026

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042
Website: http://www.wiseguyreports.com

Release ID: 270802